Finerenone in Milan
the INFINITY pooled analysis of 14,574 patients shows 24 percent less kidney failure and 20 percent less heart failure or cardiovascular death, and per the EASD subanalyses regardless of HbA1c and BMI
Finerenone at EASD 2026 in Milan: the INFINITY individual-participant pooled analysis of FIDELIO-DKD, FIGARO-DKD and FIND-CKD (14,574 participants with CKD with or without type 2 diabetes, median three years; published in The Lancet in June 2026) reduced kidney failure or sustained eGFR decline of at least 57 percent (HR 0.76), kidney failure alone (HR 0.85), heart failure hospitalisation or cardiovascular death (HR 0.80) and the combined outcome (HR 0.77), with no new hyperkalaemia signal and consistent effects with and without diabetes and on top of SGLT2 inhibitors. The Milan subgroup presentations by HbA1c (LBA 92) and BMI (LBA 31, Rossing; UMCG co-authors Heerspink and Smeijer) report consistent risk reductions across HbA1c quartiles and a BMI range of about 24 to 42; detailed subgroup numbers are not yet published. A type 1 diabetes CKD analysis builds on FINE-ONE. The message is breadth of indication rather than a new effect, in line with the ADA/EASD consensus layering of SGLT2 inhibitor, GLP-1 and finerenone.
